Skip to content
2000
Volume 21, Issue 35
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

This review highlights practical aspects related to aspirin therapy in cardiovascular diseases, specifically, the benefits and hazards in different clinical settings. Aspirin reduces one fourth of all major cardiovascular events but also increases major gastrointestinal bleeds by about half. As with other cardiovascular prevention strategies, the absolute benefit of aspirin is linearly related to the cardiovascular risk of the patient. The risk-benefit of aspirin can vary substantially in different settings: in secondary prevention, the benefits usually outweigh the excess of major bleeding complications. In primary prevention, it is not unusual that the number of vascular events avoided equals the number of major bleeds induced by aspirin. Finally, there is a growing body of evidence suggesting that aspirin may interfere with the early stages of cancer, metastasis and mortality. For all these reasons, in this article new developments in the field directed towards individualized risk assessment strategies are also discussed.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612821666150915110322
2015-10-01
2025-05-04
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612821666150915110322
Loading

  • Article Type:
    Research Article
Keyword(s): Aspirin; GI damage; prevention cardiovascular diseases; proton pump inhibitors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test